Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib with concurrent radiotherapy versus chemoradiation followed by Firmonertinib in unresectable/inoperable EGFR-mutant stage II–III NSCLC
ChiCTR2500097458Phase 4Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Shandong First Medical University. Primary endpoint: Objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500097458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097458.